were extrapolated from earlier dose-efficacy studies and were estimated to be V4-Va of those optimal for induction of long-lasting allograft acceptance (9) The 59 rats were obtained from seven consecutive litters, randomly deployed to the three sex-matched groups, raised under controlled lighting, and allowed tap water and regular rat food. Tap water or FK 506 was given by daily gastric intubation. FK 506 (Fujisawa, Osaka, Japan) was dispersed with hydroxypropyl methylcellulose and diluted in tap water by sonication. Onset of diabetes was diagnosed by glycosuria (tested 3 times/ wk) and confirmed by nonfasted blood glucose >11.1 mM from tail vein samples for 3 consecutive days.
RESULTS
During the 90-day treatment, diabetes developed in 75, 15.7, and 0% of tap water, low-dose FK 506, and high-dose FK 506 groups, respectively (Fig. 1) , There was no mortality and very little inhibition (NS) of weight gain of the nondiabetic rats in the treatment groups (Fig, 2) . The protective effect of FK 506 often outlasted the time of treatment (Table 1) . Only five rats subsequently became diabetic (3 associated with pregnancy).
Glucose intolerance was not observed with the doses of FK 506 used in this study. In the nondiabetic control rats and the FK 506-protected rats. blood glucose levels obtained every 2 wk were normal (Fig. 3) . Three rats from group 2 and 6 rats from group 3 had normal intraperitoneal glucose tolerance tests (2 g glucose/kg body wt) before they were killed for tissues on the last day of treatment (Fig. 4) .
Other blood chemistry measurements and pancreatic insulin content were determined at the end of the FK 506 treatment in six of the nondiabetic survivors killed in group 2 and five of those killed in group 3. There was no increase of blood urea nitrogen, creatinine, glutamic-oxaloacetic transaminase, or glutamic-pyruvic transaminase compared with six nondiabetic Wistar-Furth (non-BB) rats ( acid, and 23.4% distilled H20) and sonicated vigorously for 10 min at 4°C. After centrifugation at 500 rpm for 10 min, the supernatant fractions were frozen for subsequent assays of insulin by radioimmunoassay. Pancreatic insulin content in these rats was normal (Table 2) . Histopathologically, these pancreases were free of the insulitis and periductular inflammation that was invariable in the untreated diabetic rats. In additional analyses, immunocytochemical studies were performed on tissue sections from rats in groups 1-3 and four nondiabetic Wistar-Furth controls. Guinea pig anti-human insulin antibodies (Biogenex, San Ramon, CAl and rabbit anti-human glucagon antibodies (Amersham, Ayles- o~=r==~~~==¢==r~r=~~--r--.-. kg-' . day-'; e, 2 mg . kg-' . day-') compared with their male and female water-treated siblings (0 and ., respectively). Only 5 watertreated rats were nondiabetic at 120 days.
bury, UK) have sufficient cross-reactivity with the respective rat hormones to allow immunohistochemical detection. Localization of these antibodies onto fixed paraffin-embedded tissues was visualized with the avidin-biotin procedure (Vector, Burlingame, CAl. Color was developed with 3-amino-9-ethylcarbazole (Biomeda, Foster City, CAl The entire procedure was performed on a computer-driven robot (Code-On, Fisher, Pittsburgh, PAl, which allowed the placement of parallel control slides. In nondiabetic Wistar-Furth rats, insulin-containing cells were clearly demarcated and generally inhabited the centers of the islets. Glucagon-conFate after 120 days of rats treated with FK 506 from days 30-120 of age FK 506 treated tThree other rats were used for breeding and became diabetic while pregnant at 170,175, and 180 days. Values are means ± SD. BUN, blood urea nitrogen; GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase.
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EFFECT OF FK 506 ON BB RATS taining cells formed a distinct peripheral rim around the islets. With the development of diabetes in the untreated BB rats, insulin-containing cells disappeared completely, islet size was reduced. and the cells stained only with anti-glucagon antibodies. In contrast, normal-appearing distributions of insulin-and glucagon-containing cells were observed in 5 of 6 low-dose FK 506 and 3 of 3 high-dose FK 506 rats.
DISCUSSION
These data together with other observations support the notion that FK 506 may be a successful immune intervention agent for recent-onset diabetes. The therapeutic index of FK 506 in humans is better than CsA (7, 10) , even though it is expected to have a qualitatively similar toxicity profile, including diabetogenic, neurotoxic, and nephrotoxic potential. Although the drugs are chemically unrelated, the central action of both is speculated to be inhibition of the enzyme peptidylprolyl isomerase (PPlase), which is the principal constituent of their cytosolic binding sites. The ubiquitous distribution of PPlase, including kidney and pancreas, implies that drugs that modulate it will affect multiple nonimmunologic metabolic processes (11) . However, evidence is mounting that these consequences will not vitiate the value of FK 506 in transplantation or for the treatment of autoimmune diseases (7, 10, 11) . 
